Gynecologic Oncology Articles

Genomic Testing Has Impact on Treatment Decisions in Ovarian Cancer
Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.
PARP Combos May Represent Future in Frontline Maintenance Ovarian Cancer Setting
Maintenance therapy with olaparib following chemotherapy is the new standard of care for women with BRCA–mutated ovarian cancer.
FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices
The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.
Surgeon Discusses Frontline Standard in Newly Diagnosed Ovarian Cancer
Neil Horowitz, MD, discusses surgical options for patients with newly diagnosed ovarian cancer.
Novel Strategies Emerging in Uterine Sarcomas
Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.
Reminder App With Postsurgery Instructions Well Received by Patients With Ovarian Cancer
Nearly 1 IN 5 women who undergoes ovarian cancer surgery is readmitted for complications, but a web-based app may improve patient monitoring so complications and adverse events can be addressed quickly by the patient’s care team.
Joyce F. Liu, MD, MPH, highlights the recent changes in the newly diagnosed ovarian cancer space and what the oncology field could see by the end of 2019.
Targeted Liquid Biopsy Could Be Potential Early Screening Tool for Endometrial Cancer
A targeted liquid biopsy may have the potential to serve as an early diagnostic tool for endometrial cancer.
HPV Subtypes Linked to Development of High-Grade Cervical Cancer
The presence of specific subtypes of HPV, namely HPV-16 and -18, were found to be associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.
Added Factors Put the Overall Survival Endpoint to the Test
The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.
Publication Bottom Border
Border Publication